You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
A prospective study in 35 advanced melanoma patients found that response to combined Yervoy and Opdivo was correlated with the three markers.